English
|
中文
HOME
NEWS
EVENTS
Conference
Exhibition
Laws & Regulations
About Us
CAIVD & CPCEM
CAIVD
CPCEM
VIEW
About VIEW
Editorial Board
Contact
Search
News
Home
>
News
AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer
2026-05-19
Original from: PR Newswire AstraZeneca and Roche Diagnostics Asia Pacific today announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care a..
IVD China last week: Thermo Fisher Scientific and RealBio, Dirui and TechVital, DIAN Diagnostics, ADICON, BioChain
2026-05-18
RealBio and Thermo Fisher Scientific Partner on IVD Quality Control Solutions On May 12 in Shanghai, RealBio signed a strategic agreement with Thermo Fisher Scientific to collaborate on co..
Co-Diagnostics Reports First Quarter 2026 Financial Results
2026-05-18
Original from: Co-Diagnostics Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic..
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
2026-05-18
Original from: Natera Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as ..
Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
2026-05-15
Original from: PR Newswire - Labcorp's full test menu will be available through Epic's Aura platform - Integration builds on the successful deployment of Invitae genetic testing and accelerates acc..
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15
Original from: Lucid Diagnostics Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:..
Cepheid Receives CE Marking Under IVDR for Xpert® GI Panel
2026-05-14
Original from: PR Newswire Cepheid, a Danaher company, announced today that it has received CE marking under the in vitro medical device regulation (IVDR) for the Xpert GI Panel. This multiplex PCR test ..
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
2026-05-14
Original from: business news - Delivers the only FDA-cleared ChLIA testosterone testing portfolio with direct measurement of total testosterone, free testosterone, and sex hormone-binding globulin ..
Waters Reports Strong First Quarter Following BD Biosciences and Diagnostics Acquisition
2026-05-13
Original from: Waters Corporation First Quarter 2026 Highlights - Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformanc..
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
2026-05-13
Original from: Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and desig..
86 China IVD & IVD-Related Listed Companies Release 2025 Annual Financial Reports
2026-05-12
As of 30 April 2026, a total of 86 China-listed companies related to the In Vitro Diagnostics (IVD) sector had released their 2025 annual reports, including 61 companies primarily engaged in IVD businesses and 25 comp..
IVD China last week: Sansure and Tencent Health, Dynamiker, Maxim Biotechnologies and BGI Tech, Haier Biomedical
2026-05-12
Sansure Biotech Partners with Tencent Health to Launch an AI Ecosystem for China Primary Healthcare On May 9, Sansure Biotech signed a strategic cooperation agreement with Tencent Health at..
In Vitro Diagnostic Industry in China - Blood Typing Instruments and Reagents X
2026-05-12
3.3.2 Future Development of Blood Typing Instruments Working Party on Clinical Transfusion Management, Chinese Society of Blood Transfusion investigated blood transfusion departments of 2309 hospitals in differe..
Fujirebio announces CE marking of the fully automated Lumipulse® G pTau 217 Plasma assay
2026-05-12
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA).
BD Reports Second Quarter Fiscal 2026 Financial Results
2026-05-12
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.
Total:
3753
Pages:
251
First
Prev
1
2
3
4
5
..
251
Next
End